eritoran

Eritoran is a synthetic lipid A analog and structural analogue of the lipid A portion of lipopolysaccharide (LPS). It was developed as an intravenous drug for the treatment of severe sepsis and septic shock. Eritoran acts as a potent antagonist of toll-like receptor 4 (TLR4), blocking LPS from binding to the MD2-TLR4 complex on immune cells. By inhibiting TLR4 activation, it downregulates intracellular generation of pro-inflammatory cytokines such as IL-6 and TNF-alpha in human monocytes. Despite promising preclinical results, eritoran failed to demonstrate efficacy in reducing mortality in large phase 3 clinical trials for severe sepsis, leading to discontinuation of its development[1][2][5][8].

Other names

eritoran tetrasodiumeritoran sodium